Population-representative incidence of acute-on-chronic liver failure

Journal of Clinical Gastroenterology

Volumn 50, Issue 8, 2016, Pages 670-675

  Qin, Gang ^a,b   Shao, Jian Guo ^a   Zhu, Yong Chang ^d   Xu, Ai Dong ^e   Yao, Jian Hua ^f   Wang, Xu Lin ^b   Qian, Yin Kun ^g   Wang, Hua Yu ^h   Shen, Yi ^b   Lu, Peng ^c   Wang, Lu Jun ^a  

^a The Third People's Hospital of Nantong   (China)

^b School of Public Health   (China)

^c NANTONG UNIVERSITY   (China)

^d People's Hospital of Qidong City   (China)

^e Haimen People's Hospital   (China)

^f People's Hospital of Rugao   (China)

^g Department of Obstetrics and Gynecology Rudong Third Hospital   (China)

^h Hai'an People's Hospital   (China)

Author keywords

acute on chronic liver failure; incidence; mortality

Indexed keywords

ACUTE ON CHRONIC LIVER FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; CHINA; CHRONIC HEPATITIS B; CHRONIC LIVER DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEPATITIS B VIRUS; HOSPITALIZATION COST; HUMAN; INCIDENCE; JAUNDICE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; VIRUS REACTIVATION; AGE; COMPLICATION; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ACUTE-ON-CHRONIC LIVER FAILURE; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHINA; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84965031148     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000538     Document Type: Article

References (35)

1. Bower WA, Johns M, Margolis HS, et al. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007; 102: 2459-2463.
2. Polson J, Lee WM. and American Association for the Study of Liver D. AASLD position paper: the management of acute liver failure. Hepatology. 2005; 41: 1179-1197.
3. Wigg AJ, Chinnaratha MA, Wundke R, et al. A chronic disease management model for chronic liver failure. Hepatology. 2015; 61: 725-728.
4. Ohnishi H, Sugihara J, Moriwaki H, et al. Acute-on-chronic liver failure. Ryoikibetsu Shokogun Shirizu. 1995; 19: 217-219.
5. Li LJ. Diagnostic and treatment guidelines for Iiver failure. Zhonghua Gan Zang Bing Za Zhi. 2006; 14: 643-646.
6. Li LJ. Diagnostic and treatment guidelines for Iiver failure. Zhonghua Gan Zang Bing Za Zhi. 2012; 21: 177-183.
7. Si CW, Zhuang H. Prevention and cure project of viral hepatitis. Zhonghua Gan Zang Bing Za Zhi. 2000; 8: 324-329.
8. Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009; 3: 269-282.
9. Chinese Society of Hepatology CMA and Chinese Society of Infectious Diseases CMA. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl). 2007; 120: 2159-2173.
10. Chinese Society of Hepatology. The guideline of prevention and treatment for chronic hepatitis C. Zhonghua Gan Zang Bing Za Zhi. 2004; 12: 194-198.
11. O?Shea RS, Dasarathy S, McCullough AJ, et al. Alcoholic liver disease. Hepatology. 2010; 51: 307-328.
12. Radha Krishna Y, Saraswat VA, Das K, et al. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int. 2009; 29: 392-398.
13. Abbas Z, Shazi L. Pattern and profile of chronic liver disease in acute on chronic liver failure. Hepatol Int. 2015; 9: 366-372.
14. Shen Y, Zhang J, Cai H, et al. Identifying patients with chronic hepatitis B at high risk of type 2 diabetes mellitus: a crosssectional study with pair-matched controls. BMC Gastroenterol. 2015; 15: 32.
15. Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut. 2009; 58: 1555-1564.
16. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009; 27: 6550-6557.
17. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005; 352: 2673-2681.
18. Wang JL, Du XF, Chen SL, et al. Histological outcome for chronic hepatitis B patients treated with entecavir versus lamivudine-based therapy. World J Gastroenterol. 2015; 21: 9598-9606.
19. Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014; 147: 143-151. e145.
20. Chen T, He Y, Liu X, et al. Nucleoside analogues improve the short-Term and long-Term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Clin Exp Med. 2012; 12: 159-164.
21. Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2014; 8: 453-471.
22. Olson JC, Kamath PS. Acute-on-chronic liver failure: concept, natural history, and prognosis. Curr Opin Crit Care. 2011; 17: 165-169.
23. Jalan R, Gines P, Olson JC, et al. Acute-on chronic liver failure. J Hepatol. 2012; 57: 1336-1348.
24. Chen JF, Wang KW, Zhang SQ, et al. Dexamethasone in outcome of patients with hepatitis B virus-related acute-onchronic liver failure. J Gastroenterol Hepatol. 2014; 29: 800-806.
25. Luca A, Angermayr B, Bertolini G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl. 2007; 13: 1174-1180.
26. Qin G, Shao JG, Wang B, et al. Artificial liver support system improves short- And long-Term outcomes of patients with HBV-Associated acute-on-chronic liver failure: a single-center experience. Medicine (Baltimore). 2014; 93: e338.
27. Amitrano L, Guardascione MA, Martino R, et al. Hypoxic hepatitis occurring in cirrhosis after variceal bleeding: still a lethal disease. J Clin Gastroenterol. 2012; 46: 608-612.
28. Bajaj JS, O?Leary JG, Reddy KR, et al. Survival in infectionrelated acute-on-chronic liver failure is defined by extra-hepatic organ failures. Hepatology. 2014; 60: 250-256.
29. Tandon P, Abraldes JG, Keough A, et al. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh Class, and effects of antibiotics. Clin Gastroenterol Hepatol. 2015; 13: 1189-1196. e1182.
30. Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011; 53: 774-780.
31. Hessel FP, Bramlage P, Wasem J, et al. Cost-effectiveness of the artificial liver support system MARS in patients with acuteon-chronic liver failure. Eur J Gastroenterol Hepatol. 2010; 22: 213-220.
32. Qin G, Shen Y, Shao JG, et al. Combination of artificial liver support system and nucleoside analogue treatment improves long-Term outcomes of patients with HBV-Associated acute-onchronic liver failure: a single-center experience. J Viral Hepat. 2015; 22: 46-46.
33. Thanapirom K, Treeprasertsuk S, Komolmit P, et al. Comparison of long-Term outcome of patients with Wilson?s disease presenting with acute liver failure versus acute-on-chronic liver failure. J Med Assoc Thai. 2013; 96: 150-156.
34. Ni YH. Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol. 2011; 46: 1-8.
35. Zein CO, Levy C, Basu A, et al. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol. 2005; 100: 48-55.